ClinicalTrials.gg
RecruitingNCT06786676Updated May 11, 2026

A Phase 1 Clinical Trial to Investigate the Safety, Tolerability, and Pharmacokinetics of AS-S603 in Healthy Participants

A Phase 1 interventional study of AS-S603 and Placebo in Healthy, sponsored by Amyloid Solution Inc. Recruiting at 1 site in South Korea. Open to participants aged 19 Years to 85 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-11.

Sponsored by Amyloid Solution Inc · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started May 2025; still recruiting 1 year 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
88
Allocation
Randomized
Ages
19 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 174 studies in Alzheimer Disease with a site in Korea, Republic of — 34 open to participants now, 46 under way, 16 of them phase 3. Alzheimer Disease · Korea, Republic of.

Planned enrollment
106th of 157
88 · median 206
Started
2025
with 16 others
Phase 1
20 of 174
4 open now
Primary completion
2026-12
later than 12 of 45 live
Registered
153rd of 174
by date

Among the 174 studies in Alzheimer Disease with a site in Korea, Republic of, this one is the 106th largest by planned enrollment of the 157 interventional ones that give a count, is one of 17 that started in 2025, is one of 20 in phase 1, reaches primary completion later than 12 of the 45 other live ones, and was the 153rd registered.

Alzheimer Disease

3,972 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

34 of the 174 studies in Alzheimer Disease with a site in Korea, Republic of are open now. Recruiting first, the newest first:

28 more — sign in →

All 34 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 645 Alzheimer Disease studies recruiting now, 282 (44%) set no upper age limit and 57 (9%) stop at 75 or younger; 34 take children under 18; 288 take healthy volunteers.

This study: 19 Years to 85 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 174 studies in Alzheimer Disease with a site in Korea, Republic of, or all of them as a file.
02

Study summary

This trial is a randomized, double-blind, placebo-controlled, single- and multiple-oral administration, phase 1 clinical trial to investigate the safety, tolerability, and pharmacokinetics of AS-S603 in healthy Korean or Caucasian adults and Korean elderly people.

AS-S603 is an orally administered agent developed by Amyloid Solution Inc to treat Alzheimer's disease (AD). It is a small molecule compound that targets and dissolves amyloid-beta (Aβ) and tau aggregates, two key pathologies present in the extracellular and intracellular spaces of brain cells in AD.

03

Conditions studied

  • Healthy

Keywords

  • AD
  • Alzheimer Disease
  • AS-S603
  • Mild Cognitive Impairment
04

Who can participate

Ages eligible
19 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy Korean adult volunteers aged 19 to 50 years at the time of screening (single dose study)
  • Healthy Korean or Caucasian adult volunteers aged 19 to 50 years at the time of screening (multiple dose study dose groups 1-4)
  • Healthy elderly Korean volunteers aged 65 to 85 years at the time of screening (multiple dose study dose group 5)
  • Individuals with a body weight of ≥ 50.0 kg and ≤ 90.0 kg and a of ≥ 18.5 kg/m2 and ≤ 29.9 kg/m2 at the time of screening
  • Individuals who have given written consent on a voluntary decision to participate and agree to adhere to the precautions after being fully informed of and completely understanding this clinical trial

Exclusion criteria

Exclusion Criteria:

  • Individuals with a disease or history in hepatobiliary, renal, nervous, immune, respiratory, endocrine, hemato-oncology, cardiovascular, urinary system, or psychiatric disorder.
  • Individuals with a history of a gastrointestinal disorder or surgery that may affect the safety, pharmacokinetic and pharmacodynamic evaluation of the product
  • Individuals who answered 'yes' to any question on the Columbia Suicide Severity Rating Scale administered at the time of screening
  • Individuals with or a history of clinically significant hypersensitivity to AS-S603 and the same class or other drugs (aspirin, antibiotics, etc.)
  • Individuals with a positive result in the serology test (, , test, syphilis test)
  • Individuals with a history of drug abuse or a positive urine screening for any drug of concern for abuse
  • Individuals who exhibited the following results on vital signs measured at a sitting position after resting, during the screening tests: Systolic blood pressure \< 80 mmHg or ≥ 140 mmHg, Diastolic blood pressure \< 45 mmHg or ≥ 90 mmHg
  • Individuals who exhibited interval > 450 msec (male), 470 msec (female), or clinically significant abnormal findings in rhythm on an during the screening tests
  • Individuals who exhibited any of the following results on the clinical laboratory test during the screening tests, including additional tests: or alanine transaminase > 60 IU/L, Estimated \< 90 mL/min/1.73m2
  • Individuals who had taken any prescription drug or herbal medicine within 2 weeks, or any Over-The-Counter (OTC) drugs, dietary supplements including liver supplements, or vitamin supplements within 1 week prior to the scheduled first administration of investigational product, or are expected to take them
  • Individuals who had taken an inducer or inhibitor of any drug metabolic enzyme, such as barbiturates or clarithromycin, within 1 month prior to the scheduled first administration of investigational product
  • Individuals who have participated and administered investigational product in another clinical trial within 6 months prior to the scheduled first administration of investigational product
  • Individuals who donated whole blood within 2 months, donated blood components within 1 month, or received a blood transfusion within 1 month prior to the scheduled first administration of investigational product
  • Current smokers
  • Individuals who engage in persistent alcohol consumption or are not able to avoid alcohol consumption from 3 days prior to the scheduled first administration of investigational product until the end of the clinical trial.
  • Individuals who have consumed excessive caffeine or are not able to avoid consuming caffeine-containing foods from 3 days prior to the scheduled first administration of investigational product until the end of the clinical trial.
  • Individuals who have consumed grapefruit, grapefruit juice, or grapefruit-containing foods or cannot avoid consuming grapefruit-containing foods from 3 days prior to the scheduled first administration of investigational product until the end of the clinical trial.
  • Individuals with unusual dietary habits or who cannot adhere to the standardized diet provided by the institution during the confinement period.
  • Women of , individuals whose menstrual period was not confirmed at screening, with a positive urine pregnancy test, or who do not agree to a highly effective method for at least 30 days after the last investigational product administration.
  • Men who do not agree to use condoms and ensure that their female partners use a highly effective contraceptive method throughout the entire clinical trial period and for at least 90 days after the last administration of investigational product.
  • Individuals who do not agree to refrain from donating sperm or egg throughout the entire clinical trial period and for at least 90 days after the last administration of investigational product.
  • Individuals who cannot undergo cerebrospinal fluid (CSF) tapping (for groups requiring CSF tapping)
  • Individuals determined to be ineligible for participation in the clinical trial by the investigators due to other reasons
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
88 participants (estimated)

Study arms

  • Experimental
    Test group (AS-S603)

    Korean and Caucasian Participants

    Drug: AS-S603

  • Placebo comparator
    Placebo group (Placebo of AS-S603)

    Korean and Caucasian Participants

    Drug: Placebo

Interventions

  • DrugAS-S603

    Oral administration of AS-S603 tablet

  • DrugPlacebo

    Oral administration of Placebo tablet

06

What researchers measure

Primary outcomes

  1. Number of adverse events (AEs)

    Time frame: Up to Day 27

  2. Maximum observed concentration (Cmax)

    Time frame: Up to Day 18

  3. Time of maximum observed concentration (Tmax)

    Time frame: Up to Day 18

  4. Terminal half-life (t1/2)

    Time frame: Up to Day 18

  5. Area under the concentration-time curve from the time of dosing to the time of the last measurable concentration (AUClast)

    Time frame: Up to Day 18

  6. Area under the concentration-time curve from the time of dosing extrapolated to infinity (AUCinf)

    Time frame: Up to Day 18

Other outcomes

  1. pTau217 concentration and Aβ42/40 ratio in plasma and cerebrospinal fluid (CSF)

    Exploratory pharmacodynamic evaluation based on pTau217 concentration and Aβ42/40 ratio in plasma and CSF

    Time frame: Up to day 27

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2025 (actual). Primary completion is estimated for Dec 2026, 19 months after the start.

Of 163 industry-sponsored phase 1 interventional studies under Alzheimer Disease, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 23. This study's planned 19 months is above that.

Counting every sponsor, half of 236 studies reached it within 17 months; a quarter within 7 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 8, 2025
First posted
Jan 22, 2025
StartActual
May 26, 2025
Primary completionEst.
Dec 31, 2026
CompletionEst.
May 31, 2027
Last update
May 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06786676
Lead sponsor
Amyloid Solution Inc
Responsible party
Sponsor
First posted
Jan 22, 2025
Start date
May 26, 2025
Primary completion
Dec 31, 2026 (estimated)
Completion
May 31, 2027 (estimated)
Last update
May 11, 2026

Study contacts

In Young Chang
Contact
clinical@amyloidsolution.com
+82-31-8092-3840

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion